




WHERE TECHNOLOGY COMES TO **LIFE**

Q1 2026



Forward Looking Statement

This presentation contains forward-looking statements within the Israeli Securities Law, 1968, the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws, as amended, regarding Pluri Inc. and/or its subsidiaries (collectively the “Company” or “Pluri”), to the extent such statements do not relate to historical or current facts. For example, the Company is using forward-looking statements when it discusses the potential benefits of its solutions and the solutions of its subsidiaries and joint venture; its ability to create a collaborative network of ventures and partnerships; the ability of its technological platform; its ability to retain majority share ownership in every venture it creates; its ability to grow stronger and drive continuous innovation and success; and potential market size and growth for its solutions. Forward-looking statements are based on management’s current expectations, estimates, projections, and assumptions about future events, and are subject to several factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These statements are not guarantees of future performance and involve certain risks, uncertainties, and assumptions about the Company, which are difficult to predict, including projections of the Company’s future financial results, its anticipated growth strategies, and anticipated trends in its business and in the market generally. Therefore, actual future results, performance and trends may differ materially from these forward-looking statements due to a variety of factors, including, without limitation: changes in technology and market requirements; the Company may encounter delays or obstacles in launching and/or successfully completing its proposed plans, including research and development; its products may not be approved by regulatory agencies, their technology may not be validated as they progress further and their methods may not be accepted; it may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with its processes; its products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real world settings; its patents may not be sufficient; its products may harm recipients or consumers; changes in legislation with an adverse impact; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of the Company or its joint ventures to differ materially from those contemplated in such forward-looking statements. The factors listed above are not exclusive, and further information is contained in the Company’s Annual Report on Form 10-K and other reports on file with the U.S. Securities and Exchange Commission. All forward-looking statements speak only as of the date of this presentation. Although the Company believes the expectations reflected in the forward-looking statements contained herein are reasonable, it cannot guarantee future results, level of activity, performance, or achievements. Moreover, neither the Company nor any other person assumes responsibility for the accuracy and completeness of any of these forward-looking statements.

This presentation does not constitute an offer to sell, or the solicitation of an offer to buy, any securities of the Company. The information to be presented is not intended to replace the need to review the Company’s formal filings with the U.S Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K and any subsequent filings, prior to making any investment in the Company’s securities. In case of any inconsistencies between the information provided in this presentation and the Company’s regulatory filings, the latter will prevail. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q filed with the U.S. Securities and Exchange Commission and available on the SEC’s website, www.sec.gov.

Pluri Venture Creation



Company

- Nasdaq (PLUR), TASE (PLUR.Ta)
- Cash & Deposits: ~\$17 million (as of June 30, 2025)
- **\$10M strategic investment** and expansion into cacao market
- Based In Israel With **Global Presence** (USA and Europe)
- Rich IP Portfolio With **~250 Patents** Globally
- In-house **GMP Manufacturing Facility**
- **Two Decades Of Experience** In Cell Processing And Mass Scale Technology Development



Sectors

plurihealth Regenerative Medicine and wellness

plurifood Cultivated Meat

pluricdm Contract Development and Manufacturing Organization

pluriagtech Cell-Based Agriculture



Partners



From Single Cells To Sustainable Solutions

Pluri harnesses the power of cells, the building blocks of life, to deliver eco-friendly solutions that aim to enhance individual well-being and drive positive global change

Pluri leverages two decades of experience and proprietary platform for cell-based solutions to create **a collaborative network of ventures and partnerships**



Eight Billion Lives. **One** Planet. **Zero** Time to Waste.



Aging and Health



Climate Change



Food Security



Sustainability

**A growing, aging world urgently needs
scalable, sustainable solutions**

Pluri Technological Platform

Cell-based innovations, powered by validated technology

Innovative

- **Patented 3D cell expansion**
High-quality cells produced in large quantities
- **Versatile cell source and types**
Compatible with human, animal, and plant cells
- **Modular production system**
Reduces costs and minimizes ecological impact

Validated

- **Automated, scalable process**
Efficient and fully controlled
- **In-house GMP facility**
Ensures quality and compliance with standards
- **Consistent batch production**
Proven reliability from batch to batch



Bio-Farming: Industrial Scale Production



PluriMatrix™

Growing the Future of Food with Cultivated Meat

ever after
FOODS

Ever After Foods leverages Pluri's cell expansion technology to produce mass scale, cost-effective food products in an efficient and sustainable manner, aiming to solve the industry's scalability challenges



Environmental

- Less land and water are required
- Fewer greenhouse gases
- Less agriculture-related pollution



Ethical

- Adheres to ethical animal welfare standards



Consumer

- Natural flavor modification
- Safe modification for healthier food and raw materials

Spreading Risks Across Multiple Verticals

Cultivated coffee

100% ownership



coffeesai

Cultivated cacao

79% ownership

kokomodo
Cultivating Cacao's Future

Cell-based agriculture

- Funded POC with ICL
- Funded POC with global Agriculture Corp.

pluriagtech

plurihealth

Medical aesthetics & wellness



100% ownership

Acute Radiation Syndrome

- \$2.2M funded by U.S. gov
- Hemafund collab- advancing availability in Ukraine

Immunotherapy

Osteoarthritis

€7.5M funding for PROTO consortium

Global contract for developing and manufacturing Cell-based treatment

Significant source of income,
annual growth rate >50%

pluricdmo

plurifood

Cultivated meat

69% ownership at a value of \$62 million



Knowhow
and expertise

Validated
technology
and robust IP

Deep market
understanding and
strong partnerships

Infrastructure
and corporate
services

GMP facility
with operations
and QA resources





Partnership that Becomes Independence: a Proven Path to Value Creation

**Pluri holds majority ownership in all
companies in which it is a partner**

Growing the Future of Food with Cultivated Meat

ever after
FOODS

Ever After Foods leverages Pluri's cell expansion technology to produce mass scale, cost-effective food products in an efficient and sustainable manner, aiming to solve the industry's scalability challenges



Environmental

- Less land and water are required
- Fewer greenhouse gases
- Less agriculture-related pollution



Ethical

- Adheres to ethical animal welfare standards



Consumer

- Natural flavor modification
- Safe modification for healthier food and raw materials

Ever After Foods Milestones

ever after
FOODS

Jan.
2022

Collaboration between
Pluri and Tnuva announced

 CELL-BASED
SOLUTIONS.
AT SCALE. ~84.2% ownership

 ~15.8% ownership

- Tnuva invested \$7.5 million according to a **\$40 million pre-money valuation**
- Pluri granted exclusive global royalty-bearing **license to use its IP and expertise**

Mar.
2023

Launch of a **scalable platform** for **cost effective production** of cultivated meat products

Jun.
2024

\$10 million investment round led by **leading global corporates**

- License extended to include cultivated fish
- **Post investment Pluri holds 69%**

Feb.
2025

Ever After Foods and **Bühler collaborate to scale cultivated meat production** and distribution

2026

Expected completion of manufacturing system development, initiation of regulatory processes, and receipt of initial regulatory approvals in selected markets

Reimagining Coffee Without Ecological Cost



Climate Change

Global coffee production expected to decrease by half in the next 30 years due to global warming



Land Shortage

Land suitable for growing coffee expected to reduce by up to 50% by 2050



Price Instability

U.S. coffee import prices have risen by over 65%. Prices changed from \$390 cents per kg to \$624 and back to \$419 cents per kg (2009-2023)



Carbon Footprint

126 billion kg of CO2 emissions per year
140 liters of water required to produce a single cup of coffee



Sources: NIH, World Coffee Research, World Economic Forum, ICO, Mordor Intelligence, GlobeNewswire

Designing production scale system (Production N system)



Purpose

Designing system with 10,000 PluriMatrix chambers for plant cell growth (N system)



System design

10,000 L chambers and up to 7 chambers in parallel




Expected output

Up to 84,000kg wet or 10,000kg dry

Annual production per system = **140T**
Annual production of **~500,000 coffee plants**

The Coffeesai Solution uses 100% Real Coffee

 coffeesai



A Consistent Methodology for Rapid, De-risked Venture Creation



Coffeesai demonstrates the potential creation of a promising company within a single year

**Jan.
2024**



Internal POC
(funded by Pluri)

**May
2024**



Company
creation,
CEO
and team
recruitment

**Sep.
2024**



Product
prototype

**H2
2025**



POC deals with
global partners

2026



Completion of product POC
with the Japanese partner

key milestone Regulatory
submissions in the U.S. and
Israel

Cacao at risk due to climate change



Unstable supply

Climate change, diseases affecting cacao trees, and dry seasons are reducing global cacao production



Complex supply chain

High carbon footprint resulting from transportation



Inconsistent quality

Heavy metals, pesticides, and inconsistencies in the production process can affect the quality of the product



Rising prices

In 2024, cocoa prices soared by over 170%, reaching a record high of over \$11,000 per ton. The International Cocoa Organization forecasts a shortage of around 400,000 tons of cocoa in 2025, which could lead to further price increases



Cocoa market growth

In 2023, the global cocoa market was valued at approximately \$13.5 billion and is expected to grow at an annual rate of 8.2%, reaching \$23.5 billion by 2030



Kokomodo's achievements

- Stable and scalable **14 cacao cell lines**
- Health-promoting **antioxidants** and **high nutrition values**
- **Flavor and aroma** profiles
- Scaling up from lab-scale to **semi-industrial production** with proven POC



Kokomodo Milestones

kokomodo
Cultivating Cocoa's Future

**Feb.
2024**



Company founded by Plantae Bioscience, The Kitchen (a Strauss Group company), and Tal Govrin. An investment of approximately 2.5 million NIS was made for initial feasibility

**May
2025**



Completion of acquisition by Pluri



~79% ownership

**H2
2025**



POC deals with global partners

2026



Completion of development processes to scale up production volumes

Regulatory submissions in the U.S. and Israel



Health and Wellbeing

Revolutionizing Beauty and Wellness Through Cell Science



Market Opportunity

The global aesthetics and wellness industry exceeds \$200B, driven by demand for evidence-based, biotech-powered, and clean solutions



Science-Driven Innovation

CellaV develops bioactive ingredients and finished products rich in exosomes, cytokines, and growth factors - designed to rejuvenate, repair, and elevate skin vitality



From Therapy to Lifestyle

Cellav transforms decades of cell-science expertise into next-generation solutions for aesthetics, health, and well-being



Partnership & Growth

Cellav expects to collaborate with brands, clinics, and distributors offering ingredients, finished products and co-development - delivering science-based, ready-to-market solutions



Stem Cell Use Authorization in the US



Premium Aesthetics Solutions



The U.S. Food and Drug Administration (FDA) has authorized Mayo Clinic to offer mesenchymal stem cells as part of the Regenerative Nephrology Compassionate Use Program.





Leveraging CDMO Capabilities to Create Revenue and Value

Pluri's Contract Development Manufacturing Organization



With more than 15 years of GMP manufacturing expertise, Pluri is leveraging its skilled team, 47,000 sq ft facility and logistics capabilities for cell therapy CDMO clients



GMP Certified

- Facility compliant to Europe, US and Israel standards
 - Local presence in Europe and US for client support
 - EU GMP certification
 - Israel MoH (compliant to EU regulations) facility approval



Facility Overview

- Production Level Area: 19,000 sq ft
- Clean Rooms Area: 4 segregated suits, 6,500 sq ft
- Process & Analytical Labs: 107,000 sq ft
- Total Area: 47,000 sq ft



PLX-R18 for Acute Radiation Syndrome

ARS is caused by exposure to high amounts of ionizing radiation, such as in nuclear reactor accidents or warfare

Studies and Collaborations


- The U.S. National Institutes of Health (NIH) and the Department of Defense (DoD) funded \$2.2 million out of the total \$4.2 million budget originally allocated for the studies
- In April 2025, Pluri was informed that funding for the project would be discontinued due to significant budget cuts in the United States
- Pluri is currently working to secure alternative support from several partners
- Collaboration agreement with Hemafund to enhance Ukraine's radiation emergency preparedness

FDA

- FDA cleared Investigational New Drug (IND) application for PLX-R18 for the treatment of ARS in case of nuclear events
- Received FDA Orphan Drug Designation



Survival Rate

Significant increase (68%) vs placebo ($p < 0.0001$)*



Blood Lineages

Significant recovery of blood lineages ($p < 0.001$)



Our Collaborative Network of Partnerships


Regulatory



EUROPEAN MEDICINES AGENCY



Scientific Collaborations and Partnering



Funding



Key Milestones for 2026



Medical aesthetics and placental cells:
Accelerating product commercialization in the US and Europe, starting significant sales and first commercial-scale revenues during 2026.



Achieving significant milestones with existing strategic partners, expanding collaborations with additional partners, and regulatory filings in the US and Israel.



Completing a critical technological goal and launching an advanced production system, with a production capacity of hundreds of KGs per week in preparation for commercial scale.



Expanding CDMO activities by signing agreements with new customers and increasing the order backlog.

Our Team



Yaky Yanay
CEO & President



Liat Zalts
Chief Financial Officer



Lior Raviv
Chief Technology Officer



Dr. Michal Sheleg, PhD
VP Clinical Development



Nimrod Bar Zvi
Chief Commercial Officer



Dr. Arthur Machlenkin, PhD
Chief Scientific Officer



Nofar Glaich-Dabach
VP Human Resources



Orly Amiran
Chief Quality Officer



Efrat Kaduri
Chief BD Officer - Pharma



Ori Shalem
VP Operations & Manufacturing

THANK YOU.

Our cell-based innovations are aimed at transforming industries with a goal to create a more sustainable, healthier world. From the food we eat to the medicine we consume, we are building solutions that can potentially serve humanity, one breakthrough at a time.



For further info: investor.relations@pluri-biotech.com